share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'First Subject Has Been Dosed in the First-in-man Phase 1 Clinical Study of SAB-142, the First Fully-human Anti-thymocyte Immunoglobulin (ATG)'

Benzinga ·  Nov 29, 2023 07:00
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga 'First Subject Has Been Dosed in the First-in-man Phase 1 Clinical Study of SAB-142, the First Fully-human Anti-thymocyte Immunoglobulin (ATG)'
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment